Neurofibromatosis type 1 natural history, complications and prognosis: Difference between revisions
MoisesRomo (talk | contribs) No edit summary |
MoisesRomo (talk | contribs) No edit summary |
||
Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
'''[[Neurofibromatosis Type 1]]''' manifestations vary widely among patients , from individuals with absent [[symptoms]] to rapidly progressive disorders. The most common complication of [[neurofibromatosis type 1]] is [[disfigurement]] due to skin lesions. [[Prognosis]] will depend on the number of [[commorbidities]], but it is usually moderately good. [[Life expectancy]] is usually reduced by 8-12 years, being [[Cancer|malignant tumors]] the most common cause of death. | |||
==Natural History, Complications, and Prognosis== | ==Natural History, Complications, and Prognosis== | ||
Line 22: | Line 19: | ||
** [[Optic nerve glioma|Optic gliomas]] develope in the first 6 years of life.<ref name="pmid203012882" /> | ** [[Optic nerve glioma|Optic gliomas]] develope in the first 6 years of life.<ref name="pmid203012882" /> | ||
** [[Scoliosis]] develops between age 6 and 10.<ref name="pmid203012882" /> | ** [[Scoliosis]] develops between age 6 and 10.<ref name="pmid203012882" /> | ||
** Malignant peripheral nerve sheath tumors | ** Malignant peripheral nerve sheath tumors usually appear around adolescence or adulthood.<ref name="pmid203012882" /> | ||
* People with [[neurofibromatosis type 1]] tend to grow below average in height and above average in [[head circumference]].<ref name="pmid105888372">{{cite journal |vauthors=Clementi M, Milani S, Mammi I, Boni S, Monciotti C, Tenconi R |title=Neurofibromatosis type 1 growth charts |journal=Am. J. Med. Genet. |volume=87 |issue=4 |pages=317–23 |date=December 1999 |pmid=10588837 |doi=10.1002/(sici)1096-8628(19991203)87:4<317::aid-ajmg7>3.0.co;2-x |url=}}</ref><ref name="pmid108176592">{{cite journal |vauthors=Szudek J, Birch P, Friedman JM |title=Growth charts for young children with neurofibromatosis 1 (NF1) |journal=Am. J. Med. Genet. |volume=92 |issue=3 |pages=224–8 |date=May 2000 |pmid=10817659 |doi= |url=}}</ref><ref name="pmid23466600">{{cite journal |vauthors=Karvonen M, Saari A, Hannila ML, Lönnqvist T, Dunkel L, Sankilampi U |title=Elevated head circumference-to-height ratio is an early and frequent feature in children with neurofibromatosis type 1 |journal=Horm Res Paediatr |volume=79 |issue=2 |pages=97–102 |date=2013 |pmid=23466600 |doi=10.1159/000347119 |url=}}</ref><ref name="pmid203012882" /> | * People with [[neurofibromatosis type 1]] tend to grow below average in height and above average in [[head circumference]].<ref name="pmid105888372">{{cite journal |vauthors=Clementi M, Milani S, Mammi I, Boni S, Monciotti C, Tenconi R |title=Neurofibromatosis type 1 growth charts |journal=Am. J. Med. Genet. |volume=87 |issue=4 |pages=317–23 |date=December 1999 |pmid=10588837 |doi=10.1002/(sici)1096-8628(19991203)87:4<317::aid-ajmg7>3.0.co;2-x |url=}}</ref><ref name="pmid108176592">{{cite journal |vauthors=Szudek J, Birch P, Friedman JM |title=Growth charts for young children with neurofibromatosis 1 (NF1) |journal=Am. J. Med. Genet. |volume=92 |issue=3 |pages=224–8 |date=May 2000 |pmid=10817659 |doi= |url=}}</ref><ref name="pmid23466600">{{cite journal |vauthors=Karvonen M, Saari A, Hannila ML, Lönnqvist T, Dunkel L, Sankilampi U |title=Elevated head circumference-to-height ratio is an early and frequent feature in children with neurofibromatosis type 1 |journal=Horm Res Paediatr |volume=79 |issue=2 |pages=97–102 |date=2013 |pmid=23466600 |doi=10.1159/000347119 |url=}}</ref><ref name="pmid203012882" /> | ||
* [[Precocious puberty]] and [[delayed puberty]] is more common in individuals with neurofibromatosis type 1 than the general population.<ref name="pmid109699312">{{cite journal |vauthors=Virdis R, Sigorini M, Laiolo A, Lorenzetti E, Street ME, Villani AR, Donadio A, Pisani F, Terzi C, Garavelli L |title=Neurofibromatosis type 1 and precocious puberty |journal=J. Pediatr. Endocrinol. Metab. |volume=13 Suppl 1 |issue= |pages=841–4 |date=July 2000 |pmid=10969931 |doi=10.1515/jpem.2000.13.s1.841 |url=}}</ref><ref name="pmid26666878">{{cite journal |vauthors=Kocova M, Kochova E, Sukarova-Angelovska E |title=Optic glioma and precocious puberty in a girl with neurofibromatosis type 1 carrying an R681X mutation of NF1: case report and review of the literature |journal=BMC Endocr Disord |volume=15 |issue= |pages=82 |date=December 2015 |pmid=26666878 |pmc=4678666 |doi=10.1186/s12902-015-0076-4 |url=}}</ref><ref name="pmid12729406">{{cite journal |vauthors=Virdis R, Street ME, Bandello MA, Tripodi C, Donadio A, Villani AR, Cagozzi L, Garavelli L, Bernasconi S |title=Growth and pubertal disorders in neurofibromatosis type 1 |journal=J. Pediatr. Endocrinol. Metab. |volume=16 Suppl 2 |issue= |pages=289–92 |date=March 2003 |pmid=12729406 |doi= |url=}}</ref><ref name="pmid203012882" /> | * [[Precocious puberty]] and [[delayed puberty]] is more common in individuals with neurofibromatosis type 1 than the general population.<ref name="pmid109699312">{{cite journal |vauthors=Virdis R, Sigorini M, Laiolo A, Lorenzetti E, Street ME, Villani AR, Donadio A, Pisani F, Terzi C, Garavelli L |title=Neurofibromatosis type 1 and precocious puberty |journal=J. Pediatr. Endocrinol. Metab. |volume=13 Suppl 1 |issue= |pages=841–4 |date=July 2000 |pmid=10969931 |doi=10.1515/jpem.2000.13.s1.841 |url=}}</ref><ref name="pmid26666878">{{cite journal |vauthors=Kocova M, Kochova E, Sukarova-Angelovska E |title=Optic glioma and precocious puberty in a girl with neurofibromatosis type 1 carrying an R681X mutation of NF1: case report and review of the literature |journal=BMC Endocr Disord |volume=15 |issue= |pages=82 |date=December 2015 |pmid=26666878 |pmc=4678666 |doi=10.1186/s12902-015-0076-4 |url=}}</ref><ref name="pmid12729406">{{cite journal |vauthors=Virdis R, Street ME, Bandello MA, Tripodi C, Donadio A, Villani AR, Cagozzi L, Garavelli L, Bernasconi S |title=Growth and pubertal disorders in neurofibromatosis type 1 |journal=J. Pediatr. Endocrinol. Metab. |volume=16 Suppl 2 |issue= |pages=289–92 |date=March 2003 |pmid=12729406 |doi= |url=}}</ref><ref name="pmid203012882" /> | ||
Line 36: | Line 33: | ||
**[[Brain tumors]]<ref name="pmid29478615" /> | **[[Brain tumors]]<ref name="pmid29478615" /> | ||
**Wandering problems due to [[scoliosis]] and/or [[kyphosis]]<ref name="pmid29478615" /> | **Wandering problems due to [[scoliosis]] and/or [[kyphosis]]<ref name="pmid29478615" /> | ||
**Malignant degeneration of neurofibromas into malignant | **Malignant degeneration of neurofibromas into malignant peripheral nerve sheath tumor (this occurs in 10-12% of the cases)<ref name="pmid29478615" /> | ||
===Prognosis=== | ===Prognosis=== |
Revision as of 14:30, 1 September 2020
Neurofibromatosis type 1 Microchapters |
Differentiating Neurofibromatosis type 1 from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Neurofibromatosis type 1 natural history, complications and prognosis On the Web |
American Roentgen Ray Society Images of Neurofibromatosis type 1 natural history, complications and prognosis |
FDA on Neurofibromatosis type 1 natural history, complications and prognosis |
CDC on Neurofibromatosis type 1 natural history, complications and prognosis |
Neurofibromatosis type 1 natural history, complications and prognosis in the news |
Blogs on Neurofibromatosis type 1 natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Moises Romo M.D.
Overview
Neurofibromatosis Type 1 manifestations vary widely among patients , from individuals with absent symptoms to rapidly progressive disorders. The most common complication of neurofibromatosis type 1 is disfigurement due to skin lesions. Prognosis will depend on the number of commorbidities, but it is usually moderately good. Life expectancy is usually reduced by 8-12 years, being malignant tumors the most common cause of death.
Natural History, Complications, and Prognosis
Natural history
- Manifestations vary widely among patients with neurofibromatosis type 1, from individuals with absent symptoms to rapidly progessive disorders.[1]
- Characteristics of neurofibromatosis type 1 appear at different ages,[1][2][3][4] among them:
- Bone manifestations appear from birth.[1]
- Plexiform neurofibromas appear usually around 1 year of age.[1]
- Cafe au lait spots appear in the first 5 years of life.[1]
- Optic gliomas develope in the first 6 years of life.[1]
- Scoliosis develops between age 6 and 10.[1]
- Malignant peripheral nerve sheath tumors usually appear around adolescence or adulthood.[1]
- People with neurofibromatosis type 1 tend to grow below average in height and above average in head circumference.[5][6][7][1]
- Precocious puberty and delayed puberty is more common in individuals with neurofibromatosis type 1 than the general population.[8][9][10][1]
Complications
- Common complications of neurofibromatosis type 1 include:
- Depression and social anxiety[11]
- Chronic pain, numbness, and/or paralysis due to the peripheral nerve sheath tumors[11]
- Blindness due to optic nerve gliomas[11]
- Amputation due to a tibial pseudarthrosis[11]
- Disfigurement due to skin lesions[11]
- Brain tumors[11]
- Wandering problems due to scoliosis and/or kyphosis[11]
- Malignant degeneration of neurofibromas into malignant peripheral nerve sheath tumor (this occurs in 10-12% of the cases)[11]
Prognosis
- Depending on the extent of the disease progression and the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as moderately good.
- Quality of life is lower in children and adults with neurofibromatosis type 1, due to the several commorbidities and complications, many times having an incapacitating depression.[12]
- Life expectancy in patients with neurofibromatosis type 1 is usually reduced 8-21 years from the normal population.[13]
- The most common cause of death in these type of patients is due to malignant neoplasm.[13][14][15][16][17][18]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9
- ↑ DeBella K, Szudek J, Friedman JM (March 2000). "Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children". Pediatrics. 105 (3 Pt 1): 608–14. doi:10.1542/peds.105.3.608. PMID 10699117.
- ↑ Boulanger JM, Larbrisseau A (May 2005). "Neurofibromatosis type 1 in a pediatric population: Ste-Justine's experience". Can J Neurol Sci. 32 (2): 225–31. doi:10.1017/s0317167100004017. PMID 16018159.
- ↑ Williams VC, Lucas J, Babcock MA, Gutmann DH, Korf B, Maria BL (January 2009). "Neurofibromatosis type 1 revisited". Pediatrics. 123 (1): 124–33. doi:10.1542/peds.2007-3204. PMID 19117870.
- ↑ Clementi M, Milani S, Mammi I, Boni S, Monciotti C, Tenconi R (December 1999). "Neurofibromatosis type 1 growth charts". Am. J. Med. Genet. 87 (4): 317–23. doi:10.1002/(sici)1096-8628(19991203)87:4<317::aid-ajmg7>3.0.co;2-x. PMID 10588837.
- ↑ Szudek J, Birch P, Friedman JM (May 2000). "Growth charts for young children with neurofibromatosis 1 (NF1)". Am. J. Med. Genet. 92 (3): 224–8. PMID 10817659.
- ↑ Karvonen M, Saari A, Hannila ML, Lönnqvist T, Dunkel L, Sankilampi U (2013). "Elevated head circumference-to-height ratio is an early and frequent feature in children with neurofibromatosis type 1". Horm Res Paediatr. 79 (2): 97–102. doi:10.1159/000347119. PMID 23466600.
- ↑ Virdis R, Sigorini M, Laiolo A, Lorenzetti E, Street ME, Villani AR, Donadio A, Pisani F, Terzi C, Garavelli L (July 2000). "Neurofibromatosis type 1 and precocious puberty". J. Pediatr. Endocrinol. Metab. 13 Suppl 1: 841–4. doi:10.1515/jpem.2000.13.s1.841. PMID 10969931.
- ↑ Kocova M, Kochova E, Sukarova-Angelovska E (December 2015). "Optic glioma and precocious puberty in a girl with neurofibromatosis type 1 carrying an R681X mutation of NF1: case report and review of the literature". BMC Endocr Disord. 15: 82. doi:10.1186/s12902-015-0076-4. PMC 4678666. PMID 26666878.
- ↑ Virdis R, Street ME, Bandello MA, Tripodi C, Donadio A, Villani AR, Cagozzi L, Garavelli L, Bernasconi S (March 2003). "Growth and pubertal disorders in neurofibromatosis type 1". J. Pediatr. Endocrinol. Metab. 16 Suppl 2: 289–92. PMID 12729406.
- ↑ 11.0 11.1 11.2 11.3 11.4 11.5 11.6 11.7 Cimino PJ, Gutmann DH (2018). "Neurofibromatosis type 1". Handb Clin Neurol. 148: 799–811. doi:10.1016/B978-0-444-64076-5.00051-X. PMID 29478615.
- ↑ Vranceanu AM, Merker VL, Park E, Plotkin SR (September 2013). "Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature". J. Neurooncol. 114 (3): 257–62. doi:10.1007/s11060-013-1195-2. PMID 23817811.
- ↑ 13.0 13.1
- ↑
- ↑
- ↑
- ↑
- ↑